The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Ipilimumab, nivolumab & brentuximab vedotin for R/R Hodgkin lymphoma
Relapsed/refractory Hodgkin lymphoma (R/R HL) continues to pose a significant clinical challenge. Here, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, presents the preliminary safety and response data from the Phase I/II E4412 trial (NCT01896999) investigating ipilimumab and nivolumab when given together with brentuximab vedotin for the treatment of R/R HL. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
